Anika Therapeutics (ANIK) Tops Q3 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $19.68 -6.06%
EPS Growth %: +950.0%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +950.0%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.00, $0.35 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $38.27 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loews Corp. (L) Reports Q3 EPS of $1.50
- Oasis Management pushes for board changes at Vail Resorts
- Rosenblatt keeps Buy rating on Marvell after Lumentum acquisition
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
